Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Lacticaseibacillus rhamnosus & Crohn’s disease (CD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

XXX (1) - Lacticaseibacillus rhamnosus GG (LGG) & Crohn's disease (CD)
LGG does not prolong time to relapse in children with Crohn's disease (CD) when given as an adjunct to standard therapy.
Bousvaros et al. 2005 Inflamm Bowel Dis. 11(9): 833–839

XXX (2) - Lacticaseibacillus rhamnosus GG (LGG) & Crohn's disease (CD)
Lacticaseibacillus rhamnosus seems neither to prevent endoscopic recurrence at one year nor reduce the severity of recurrent lesions.
Prantera et al. 2002 Gut 51: 405–9

[XXX (3) - Lacticaseibacillus rhamnosus GG (LGG) & Crohn's disease (CD)](brain://Lzp8MBLOS0e8QWwLn5FvtQ/Xxx3Lactic…

A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease
Bousvaros et al. 2005 Inflamm Bowel Dis. 11(9): 833–839
Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG
Prantera et al. 2002 Gut 51: 405–9
Lactobacillus GG in inducing and maintaining remission of Crohn’s disease
Schultz et al. 2004 BMC Gastroenterol. 4: 5
The Potential Therapeutic Role of Lactobacillaceae rhamnosus for Treatment of Inflammatory Bowel Disease
Guo et al. 2023 Foods 12(4): 692

7/1/2026